JP2017508764A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017508764A5 JP2017508764A5 JP2016558141A JP2016558141A JP2017508764A5 JP 2017508764 A5 JP2017508764 A5 JP 2017508764A5 JP 2016558141 A JP2016558141 A JP 2016558141A JP 2016558141 A JP2016558141 A JP 2016558141A JP 2017508764 A5 JP2017508764 A5 JP 2017508764A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- liquid carrier
- macrogol
- ethanol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229960003511 macrogol Drugs 0.000 claims description 12
- -1 macrogol lauryl ethers Chemical class 0.000 claims description 8
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 claims description 6
- 229920002675 Polyoxyl Polymers 0.000 claims description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 6
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 claims description 5
- IZHVBANLECCAGF-UHFFFAOYSA-N 2-hydroxy-3-(octadecanoyloxy)propyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)COC(=O)CCCCCCCCCCCCCCCCC IZHVBANLECCAGF-UHFFFAOYSA-N 0.000 claims description 4
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims description 4
- 239000004359 castor oil Substances 0.000 claims description 4
- 235000019438 castor oil Nutrition 0.000 claims description 4
- SFNALCNOMXIBKG-UHFFFAOYSA-N ethylene glycol monododecyl ether Chemical compound CCCCCCCCCCCCOCCO SFNALCNOMXIBKG-UHFFFAOYSA-N 0.000 claims description 4
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 claims description 4
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 4
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 4
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 4
- 229960003943 hypromellose Drugs 0.000 claims description 4
- WITKSCOBOCOGSC-UHFFFAOYSA-N 2-dodecanoyloxypropyl dodecanoate Chemical compound CCCCCCCCCCCC(=O)OCC(C)OC(=O)CCCCCCCCCCC WITKSCOBOCOGSC-UHFFFAOYSA-N 0.000 claims description 3
- LLRANSBEYQZKFY-UHFFFAOYSA-N dodecanoic acid;propane-1,2-diol Chemical compound CC(O)CO.CCCCCCCCCCCC(O)=O LLRANSBEYQZKFY-UHFFFAOYSA-N 0.000 claims description 3
- 229940075507 glyceryl monostearate Drugs 0.000 claims description 3
- 239000003381 stabilizer Substances 0.000 claims description 3
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical class OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 claims description 2
- FFJCNSLCJOQHKM-CLFAGFIQSA-N (z)-1-[(z)-octadec-9-enoxy]octadec-9-ene Chemical compound CCCCCCCC\C=C/CCCCCCCCOCCCCCCCC\C=C/CCCCCCCC FFJCNSLCJOQHKM-CLFAGFIQSA-N 0.000 claims description 2
- LZDKZFUFMNSQCJ-UHFFFAOYSA-N 1,2-diethoxyethane Chemical compound CCOCCOCC LZDKZFUFMNSQCJ-UHFFFAOYSA-N 0.000 claims description 2
- IQXJCCZJOIKIAD-UHFFFAOYSA-N 1-(2-methoxyethoxy)hexadecane Chemical compound CCCCCCCCCCCCCCCCOCCOC IQXJCCZJOIKIAD-UHFFFAOYSA-N 0.000 claims description 2
- OKMWKBLSFKFYGZ-UHFFFAOYSA-N 1-behenoylglycerol Chemical compound CCCCCCCCCCCCCCCCCCCCCC(=O)OCC(O)CO OKMWKBLSFKFYGZ-UHFFFAOYSA-N 0.000 claims description 2
- WECGLUPZRHILCT-GSNKCQISSA-N 1-linoleoyl-sn-glycerol Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(=O)OC[C@@H](O)CO WECGLUPZRHILCT-GSNKCQISSA-N 0.000 claims description 2
- 239000000263 2,3-dihydroxypropyl (Z)-octadec-9-enoate Substances 0.000 claims description 2
- RZRNAYUHWVFMIP-GDCKJWNLSA-N 3-oleoyl-sn-glycerol Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](O)CO RZRNAYUHWVFMIP-GDCKJWNLSA-N 0.000 claims description 2
- 241000416162 Astragalus gummifer Species 0.000 claims description 2
- 239000001856 Ethyl cellulose Substances 0.000 claims description 2
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims description 2
- 102000009338 Gastric Mucins Human genes 0.000 claims description 2
- 108010009066 Gastric Mucins Proteins 0.000 claims description 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims description 2
- SHBUUTHKGIVMJT-UHFFFAOYSA-N Hydroxystearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OO SHBUUTHKGIVMJT-UHFFFAOYSA-N 0.000 claims description 2
- 229920002884 Laureth 4 Polymers 0.000 claims description 2
- PQMWYJDJHJQZDE-UHFFFAOYSA-M Methantheline bromide Chemical compound [Br-].C1=CC=C2C(C(=O)OCC[N+](C)(CC)CC)C3=CC=CC=C3OC2=C1 PQMWYJDJHJQZDE-UHFFFAOYSA-M 0.000 claims description 2
- 229920001363 Polidocanol Polymers 0.000 claims description 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims description 2
- 229920002669 Polyoxyl 20 Cetostearyl Ether Polymers 0.000 claims description 2
- 229920002701 Polyoxyl 40 Stearate Polymers 0.000 claims description 2
- 239000004372 Polyvinyl alcohol Substances 0.000 claims description 2
- 229920001615 Tragacanth Polymers 0.000 claims description 2
- 239000000679 carrageenan Substances 0.000 claims description 2
- 235000010418 carrageenan Nutrition 0.000 claims description 2
- 229920001525 carrageenan Polymers 0.000 claims description 2
- 229940113118 carrageenan Drugs 0.000 claims description 2
- 229960001777 castor oil Drugs 0.000 claims description 2
- 239000001913 cellulose Substances 0.000 claims description 2
- 229920002678 cellulose Polymers 0.000 claims description 2
- 229950009789 cetomacrogol 1000 Drugs 0.000 claims description 2
- 229940096516 dextrates Drugs 0.000 claims description 2
- 229940099371 diacetylated monoglycerides Drugs 0.000 claims description 2
- UYAAVKFHBMJOJZ-UHFFFAOYSA-N diimidazo[1,3-b:1',3'-e]pyrazine-5,10-dione Chemical compound O=C1C2=CN=CN2C(=O)C2=CN=CN12 UYAAVKFHBMJOJZ-UHFFFAOYSA-N 0.000 claims description 2
- 150000002170 ethers Chemical class 0.000 claims description 2
- 229920001249 ethyl cellulose Polymers 0.000 claims description 2
- 235000019325 ethyl cellulose Nutrition 0.000 claims description 2
- 229940049654 glyceryl behenate Drugs 0.000 claims description 2
- 229940074045 glyceryl distearate Drugs 0.000 claims description 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims description 2
- 229940072106 hydroxystearate Drugs 0.000 claims description 2
- 229950005770 hyprolose Drugs 0.000 claims description 2
- 229940061515 laureth-4 Drugs 0.000 claims description 2
- 229950006462 lauromacrogol 400 Drugs 0.000 claims description 2
- 229920000609 methyl cellulose Polymers 0.000 claims description 2
- 239000001923 methylcellulose Substances 0.000 claims description 2
- RZRNAYUHWVFMIP-UHFFFAOYSA-N monoelaidin Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC(O)CO RZRNAYUHWVFMIP-UHFFFAOYSA-N 0.000 claims description 2
- 229920000847 nonoxynol Polymers 0.000 claims description 2
- 229920002113 octoxynol Polymers 0.000 claims description 2
- XNGIFLGASWRNHJ-UHFFFAOYSA-L phthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-L 0.000 claims description 2
- 229920001983 poloxamer Polymers 0.000 claims description 2
- 229920000136 polysorbate Polymers 0.000 claims description 2
- 229940068965 polysorbates Drugs 0.000 claims description 2
- 239000011118 polyvinyl acetate Substances 0.000 claims description 2
- 229920002689 polyvinyl acetate Polymers 0.000 claims description 2
- 229920002451 polyvinyl alcohol Polymers 0.000 claims description 2
- 229940116423 propylene glycol diacetate Drugs 0.000 claims description 2
- 150000003445 sucroses Chemical class 0.000 claims description 2
- 235000010487 tragacanth Nutrition 0.000 claims description 2
- 229940116362 tragacanth Drugs 0.000 claims description 2
- 229920001664 tyloxapol Polymers 0.000 claims description 2
- MDYZKJNTKZIUSK-UHFFFAOYSA-N tyloxapol Chemical compound O=C.C1CO1.CC(C)(C)CC(C)(C)C1=CC=C(O)C=C1 MDYZKJNTKZIUSK-UHFFFAOYSA-N 0.000 claims description 2
- 229960004224 tyloxapol Drugs 0.000 claims description 2
- 239000000230 xanthan gum Substances 0.000 claims description 2
- 229920001285 xanthan gum Polymers 0.000 claims description 2
- 235000010493 xanthan gum Nutrition 0.000 claims description 2
- 229940082509 xanthan gum Drugs 0.000 claims description 2
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 15
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 12
- 239000007788 liquid Substances 0.000 claims 11
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims 8
- DEIYFTQMQPDXOT-UHFFFAOYSA-N sildenafil citrate Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.CCCC1=NN(C)C(C(N2)=O)=C1N=C2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(C)CC1 DEIYFTQMQPDXOT-UHFFFAOYSA-N 0.000 claims 4
- 229960002639 sildenafil citrate Drugs 0.000 claims 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 3
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 claims 1
- 239000000305 astragalus gummifer gum Substances 0.000 claims 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims 1
- 229940066429 octoxynol Drugs 0.000 claims 1
- 229960000502 poloxamer Drugs 0.000 claims 1
- VILMUCRZVVVJCA-UHFFFAOYSA-M sodium glycolate Chemical compound [Na+].OCC([O-])=O VILMUCRZVVVJCA-UHFFFAOYSA-M 0.000 claims 1
- 229940071117 starch glycolate Drugs 0.000 claims 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- KUXGUCNZFCVULO-UHFFFAOYSA-N 2-(4-nonylphenoxy)ethanol Chemical class CCCCCCCCCC1=CC=C(OCCO)C=C1 KUXGUCNZFCVULO-UHFFFAOYSA-N 0.000 description 1
- 125000003976 glyceryl group Chemical group [H]C([*])([H])C(O[H])([H])C(O[H])([H])[H] 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 229920003109 sodium starch glycolate Polymers 0.000 description 1
- 239000008109 sodium starch glycolate Substances 0.000 description 1
- 229940079832 sodium starch glycolate Drugs 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461955299P | 2014-03-19 | 2014-03-19 | |
| US61/955,299 | 2014-03-19 | ||
| PCT/IB2015/052014 WO2015140748A2 (en) | 2014-03-19 | 2015-03-19 | Sildenafil solutions and methods of making and using same |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017508764A JP2017508764A (ja) | 2017-03-30 |
| JP2017508764A5 true JP2017508764A5 (enExample) | 2018-05-10 |
| JP6744821B2 JP6744821B2 (ja) | 2020-08-19 |
Family
ID=54145440
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016558141A Expired - Fee Related JP6744821B2 (ja) | 2014-03-19 | 2015-03-19 | シルデナフィル液剤並びにその製造方法及び使用 |
Country Status (25)
| Country | Link |
|---|---|
| US (2) | US9968609B2 (enExample) |
| EP (2) | EP3119201B1 (enExample) |
| JP (1) | JP6744821B2 (enExample) |
| KR (1) | KR20160137584A (enExample) |
| CN (1) | CN106132204B (enExample) |
| AU (2) | AU2015233006B2 (enExample) |
| CA (1) | CA2942628C (enExample) |
| CL (1) | CL2016002318A1 (enExample) |
| CY (1) | CY1120187T1 (enExample) |
| DK (1) | DK3119201T3 (enExample) |
| EA (1) | EA032819B1 (enExample) |
| ES (1) | ES2668915T3 (enExample) |
| HR (1) | HRP20180773T1 (enExample) |
| HU (1) | HUE038431T2 (enExample) |
| IL (1) | IL247840B (enExample) |
| LT (1) | LT3119201T (enExample) |
| MX (1) | MX371276B (enExample) |
| NO (1) | NO2723977T3 (enExample) |
| PL (1) | PL3119201T3 (enExample) |
| PT (1) | PT3119201T (enExample) |
| RS (1) | RS57206B1 (enExample) |
| SG (2) | SG10201808038TA (enExample) |
| SI (1) | SI3119201T1 (enExample) |
| SM (1) | SMT201800268T1 (enExample) |
| WO (1) | WO2015140748A2 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NO2723977T3 (enExample) | 2014-03-19 | 2018-03-10 | ||
| JP6902372B2 (ja) * | 2017-02-28 | 2021-07-14 | ヱスビー食品株式会社 | 苦味抑制用組成物 |
| WO2019130052A1 (en) | 2017-12-26 | 2019-07-04 | Ftf Pharma Private Limited | Liquid oral formulations for pde v inhibitors |
| WO2020212931A1 (en) * | 2019-04-18 | 2020-10-22 | Vigorous Solutions Ltd. | Liquid sildenafil citrate compositions |
| CA3157765A1 (en) * | 2019-11-12 | 2021-05-20 | Richard Lawrence | Type v phosphodiesterase inhibitor compositions, methods of making them and methods of using them in preventing or treating elevated pulmonary vascular pressure or pulmonary hemorrhage |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5785984A (en) * | 1993-02-05 | 1998-07-28 | Kao Corporation | Taste-modifying method and bitterness-decreasing method |
| EP0635218B1 (en) * | 1993-02-05 | 2000-10-25 | Kao Corporation | Taste modifying method and bitter taste reducing method |
| US6548490B1 (en) | 1997-10-28 | 2003-04-15 | Vivus, Inc. | Transmucosal administration of phosphodiesterase inhibitors for the treatment of erectile dysfunction |
| TWI223598B (en) | 1998-06-22 | 2004-11-11 | Pfizer Ireland Pharmaceuticals | An intranasal pharmaceutical composition for the treatment of male erectile dysfunction or female sexual disorders, an intranasal delivery system or device and sildenafil mesylate |
| US6531114B1 (en) | 1999-04-06 | 2003-03-11 | Wm. Wrigley Jr. Company | Sildenafil citrate chewing gum formulations and methods of using the same |
| US6552024B1 (en) | 1999-01-21 | 2003-04-22 | Lavipharm Laboratories Inc. | Compositions and methods for mucosal delivery |
| US6248363B1 (en) | 1999-11-23 | 2001-06-19 | Lipocine, Inc. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
| TW200400821A (en) | 1999-11-02 | 2004-01-16 | Pfizer | Pharmaceutical composition (II) useful for treating or preventing pulmonary hypertension in a patient |
| AU3048501A (en) * | 1999-11-18 | 2001-05-30 | Natco Pharma Limited | An improved pharmaceutical composition for treating male erectile dysfunction |
| BR0108080A (pt) | 2000-02-04 | 2006-02-07 | Seo Hong Yoo | Preparação de formas de dosagem de solução clara aquosa com ácidos biliares |
| CA2417736A1 (en) | 2000-07-19 | 2002-01-24 | Lavipharm Laboratories, Inc. | Sildenafil citrate solid dispersions having high water solubility |
| US20030216407A1 (en) | 2002-01-31 | 2003-11-20 | Pfizer Inc. | Use of PDE5 inhibitors in the treatment of scarring |
| US7611728B2 (en) | 2003-09-05 | 2009-11-03 | Supernus Pharmaceuticals, Inc. | Osmotic delivery of therapeutic compounds by solubility enhancement |
| WO2005046632A2 (en) | 2003-11-17 | 2005-05-26 | Patus Ltd. | Compositions effective in altering the perception of malodor |
| CN1925860A (zh) * | 2004-01-05 | 2007-03-07 | 特瓦制药工业有限公司 | 制备西地那非碱及其柠檬酸盐的方法 |
| ATE387203T1 (de) | 2004-01-05 | 2008-03-15 | Teva Pharma | Prozesse zur herstellung von sildenafil-base und zitratsalz |
| US7727565B2 (en) | 2004-08-25 | 2010-06-01 | Cadbury Adams Usa Llc | Liquid-filled chewing gum composition |
| PT1858488E (pt) | 2005-03-14 | 2013-11-18 | Wyeth Llc | Composições de tigeciclina e métodos de preparação |
| US7556487B2 (en) | 2006-03-29 | 2009-07-07 | Intergum Gida Sinayi ve Ticaret A.S. | Apparatus for making center-filled chewing gum pieces |
| FR2906140B1 (fr) * | 2006-09-22 | 2008-12-05 | Philippe Perovitch | Forme galenique pour l'administration par voie trans-muqueuse de principes actifs |
| DE502008002360D1 (de) | 2007-06-19 | 2011-03-03 | Symrise Ag | Aromakomposition zum Verringern oder Unterdrücken von unerwünschtem bitteren und adstringierenden Eindruck |
| EP2072044A1 (en) * | 2007-12-19 | 2009-06-24 | Abbott GmbH & Co. KG | Pharmaceutical dosage form comprising a liquid or flowable core composition |
| WO2009125415A1 (en) | 2008-04-07 | 2009-10-15 | Hetero Research Foundation | Amorphous form of sildenafil citrate |
| FR2939321B1 (fr) | 2008-12-05 | 2011-08-26 | Philippe Perovitch | Dispositif de conditionnement et d'administration de principes actifs en solution hydro-alcoolique. |
| US8642270B2 (en) | 2009-02-09 | 2014-02-04 | Vm Institute Of Research | Prognostic biomarkers to predict overall survival and metastatic disease in patients with triple negative breast cancer |
| DE102010049708A1 (de) * | 2010-10-28 | 2012-05-03 | Hexal Ag | Orale pharmazeutische Filmformulierung für bitter schmeckende Arzneistoffe |
| RU2611403C1 (ru) * | 2011-12-05 | 2017-02-21 | Суда Лимитед | Составы в форме спрея для перорального введения и способы введения силденафила |
| GB2497933B (en) | 2011-12-21 | 2014-12-24 | Londonpharma Ltd | Drug delivery technology |
| KR102443057B1 (ko) * | 2012-01-18 | 2022-09-14 | 테크필즈 파마 코., 엘티디. | 폐 병태의 치료를 위한 고침투 전구약물 조성물 및 그의 약제학적 조성물 |
| WO2014151729A1 (en) | 2013-03-15 | 2014-09-25 | Irm Llc | Compounds and compositions for the treatment of parasitic diseases |
| NO2723977T3 (enExample) * | 2014-03-19 | 2018-03-10 |
-
2012
- 2012-04-16 NO NO12802846A patent/NO2723977T3/no unknown
-
2015
- 2015-03-19 EP EP15764710.8A patent/EP3119201B1/en active Active
- 2015-03-19 HR HRP20180773TT patent/HRP20180773T1/hr unknown
- 2015-03-19 CN CN201580013951.5A patent/CN106132204B/zh not_active Expired - Fee Related
- 2015-03-19 HU HUE15764710A patent/HUE038431T2/hu unknown
- 2015-03-19 KR KR1020167029017A patent/KR20160137584A/ko not_active Ceased
- 2015-03-19 AU AU2015233006A patent/AU2015233006B2/en not_active Ceased
- 2015-03-19 PL PL15764710T patent/PL3119201T3/pl unknown
- 2015-03-19 LT LTEP15764710.8T patent/LT3119201T/lt unknown
- 2015-03-19 SG SG10201808038TA patent/SG10201808038TA/en unknown
- 2015-03-19 RS RS20180533A patent/RS57206B1/sr unknown
- 2015-03-19 CA CA2942628A patent/CA2942628C/en active Active
- 2015-03-19 PT PT157647108T patent/PT3119201T/pt unknown
- 2015-03-19 ES ES15764710.8T patent/ES2668915T3/es active Active
- 2015-03-19 SM SM20180268T patent/SMT201800268T1/it unknown
- 2015-03-19 WO PCT/IB2015/052014 patent/WO2015140748A2/en not_active Ceased
- 2015-03-19 SG SG11201607507VA patent/SG11201607507VA/en unknown
- 2015-03-19 EP EP18161634.3A patent/EP3372083A1/en not_active Withdrawn
- 2015-03-19 EA EA201691871A patent/EA032819B1/ru unknown
- 2015-03-19 DK DK15764710.8T patent/DK3119201T3/en active
- 2015-03-19 JP JP2016558141A patent/JP6744821B2/ja not_active Expired - Fee Related
- 2015-03-19 SI SI201530249T patent/SI3119201T1/en unknown
- 2015-03-19 MX MX2016012154A patent/MX371276B/es active IP Right Grant
-
2016
- 2016-09-14 CL CL2016002318A patent/CL2016002318A1/es unknown
- 2016-09-15 IL IL247840A patent/IL247840B/en active IP Right Grant
- 2016-09-15 US US15/265,897 patent/US9968609B2/en not_active Expired - Fee Related
-
2018
- 2018-04-12 US US15/951,197 patent/US10211534B2/en active Active
- 2018-05-03 CY CY20181100459T patent/CY1120187T1/el unknown
- 2018-10-16 AU AU2018250378A patent/AU2018250378B2/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017508764A5 (enExample) | ||
| Gazi et al. | Clustering of cardiovascular risk factors in rheumatoid arthritis: the rationale for using statins | |
| ES2505116T3 (es) | Composición farmacéutica sólida que comprende amlodipino y losartán con estabilidad mejorada | |
| JP2019147832A5 (enExample) | ||
| ES2365639T3 (es) | Ectoína para el tratamiento de fugas vasculares. | |
| JP2013518056A5 (enExample) | ||
| JP2020007356A5 (enExample) | ||
| US10537570B2 (en) | Use of pimobendan for the reduction of heart size and/or the delay of onset of clinical symptoms in patients with asymptomatic heart failure due to mitral valve disease | |
| JP2017516848A5 (enExample) | ||
| JP2011201907A5 (enExample) | ||
| JP2018529742A5 (enExample) | ||
| RU2012136147A (ru) | Антимикробные агенты и способы их применения | |
| EA201600118A1 (ru) | Жидкая водная фармацевтическая композиция с консервантами, содержащая этерифицированные производные циклодекстрина | |
| AR061011A1 (es) | Suspension acuosa estable | |
| CL2017001186A1 (es) | Comprimido multicapa que contiene un fármaco inestable a la luz | |
| WO2014027334A2 (es) | Composicion farmacéutica oral en forma de microesferas y proceso de elaboración | |
| JP2013166781A5 (enExample) | ||
| SI3119201T1 (en) | Sildenafil solutions and procedures for their manufacture and use | |
| EA200870546A1 (ru) | Стабильные водные суспензии | |
| EP4173619A3 (en) | New acetaminophen compound composition without side effect to liver | |
| JP2020510619A5 (enExample) | ||
| JP2021119164A5 (enExample) | ||
| MX2019007239A (es) | Nueva formulacion que comprende un derivado de bencimidazol. | |
| JP2015536995A5 (enExample) | ||
| JP6852122B2 (ja) | Ｃｙｒ６１及びｖｅｇｆ媒介性の状態の治療 |